Brief: Reata Pharmaceuticals Gets Fast Track Designation From The FDA For Omaveloxolone For The Treatment Of Friedreich'S Ataxia
19/11/2021 02:01
Nov 18 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FROM
THE
FDA FOR OMAVELOXOLONE FOR THE TREATMENT OF FRIEDREICH’S ATAXIA
* REMAIN COMMITTED TO SUBMITTING OUR NEW DRUG APPLICATION
DURING
Q1 OF 2022
Source text for Eikon: ID:nBw3tfxMha
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer